Background and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been fully verified yet. Approach and Results: We retrospectively collected the data on the whole clinical course of 877 patients who received any MTAs as first-line systemic therapy for advanced HCC between June 2009 and March 2019. The study population was divided into 3 groups according to the date of first-line MTA administration (period 1: 2009–2012, n = 267; period 2: 2013–2016, n = 352; period 3: 2017–2019, n = 258). Then, we compared the number of MTAs used, overall survival (OS), and MTA treatment duration among the 3 groups. Analysis was also performed separately for advanced-stage and nonadvanced-stage HCC. The proportion of patients who received multiple MTAs was remarkably increased over time (1.1%, 10.2%, and 42.6% in periods 1, 2, and 3, respectively, p #x3c; 0.001). The median OS times were prolonged to 10.4, 11.3, and 15.2 months in periods 1, 2, and 3, respectively (p = 0.016). Similarly, the MTA treatment durations were extended (2.7, 3.2, and 6.6 months in periods 1, 2, and 3, respectively; p #x3c; 0.001). We confirmed that the correlation between OS and MTA treatment duration was strengthened (period 1: 0.395, period 2: 0.505, and period 3: 0.667). All these trends were pronounced in the patients with advanced-stage HCC but limited in the patients with nonadvanced-stage HCC. Conclusions: The availability of multiple MTAs had steadily improved the prognosis of patients with advanced HCC patients, particularly advanced-stage HCC patients.
Liver Cancer

中文翻译：

---

分子靶向药物对晚期肝细胞癌患者生存影响的演变

背景和目的：随着多种分子靶向药物 (MTA) 的出现，晚期肝细胞癌 (HCC) 患者的预后有望得到改善。然而，顺序 MTA 可用性的影响尚未得到充分验证。方法与结果：我们回顾性收集了 2009 年 6 月至 2019 年 3 月期间接受任何 MTA 作为晚期 HCC 一线全身治疗的 877 例患者的整个临床过程的数据。研究人群根据治疗日期分为 3 组。一线 MTA 管理（第 1 期：2009-2012， n = 267；第 2 期：2013-2016， n = 352；第 3 期：2017-2019， n= 258)。然后，我们比较了 3 组中使用的 MTA 数量、总生存期 (OS) 和 MTA 治疗持续时间。还分别对晚期和非晚期 HCC 进行了分析。随着时间的推移，接受多次 MTA 的患者比例显着增加（第 1、2 和 3 期分别为 1.1%、10.2% 和 42.6%，p #x3c；0.001）。在第 1、2 和 3 期，中位 OS 时间分别延长至 10.4、11.3 和 15.2 个月（p = 0.016）。同样，MTA 治疗持续时间延长（在第 1、2 和 3 期分别为 2.7、3.2 和 6.6 个月；p#x3c; 0.001)。我们证实 OS 和 MTA 治疗持续时间之间的相关性得到了加强（第 1 期：0.395，第 2 期：0.505，第 3 期：0.667）。所有这些趋势在晚期 HCC 患者中都很明显，但在非晚期 HCC 患者中受到限制。结论：多种 MTA 的可用性稳步改善了晚期 HCC 患者，尤其是晚期 HCC 患者的预后。
肝癌